Clinical trial NCT02255513: A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD
Official title: A Phase III Clinical Endpoint Evaluation Study Examining the Safety and Efficacy of HLD200 in Pediatric Subjects With Attention-Deficit Hyperactivity Disorder.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Attention Deficit Hyperactivity Disorder
Lead sponsor: Ironshore Pharmaceuticals and Development, Inc
Sponsor class: OTHER
First posted: 2014-10-02
Enrollment: 43
Sex: ALL
Minimum age (years): 6
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will examine the efficacy and safety of HLD200 in patients age 6-12 years with ADHD using a classroom study design.

Detailed description: The study consists of two distinct treatment phases. The first is the 6-week open-label, treatment optimization phase during which subjects are titrated to an optimal daily dose of HLD200. Subjects are then randomized to receive either optimal HLD200 or matched placebo treatment for an additional week prior to final testing during a laboratory school day.

Eligibility criteria: Inclusion Criteria:

* Male and female children (6-12 years at study entry)
* Previous diagnosis of ADHD and confirmation using the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)
* Able to swallow treatment capsules
* Available for entire study period
* Provision of informed consent (from the parent\[s\] and/or legal representative\[s\]) and assent (from the subject)
* Female subjects of childbearing potential (i.e., post-menarche) required to have a negative result on urine pregnancy test (and will be given specific instructions for avoiding pregnancy during trial).

Exclusion Criteria:

* Any known history or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, ophthalmologic disease
* Presence of any significant physical or organ abnormality
* Any illness during the 4 weeks before this study
* Comorbid psychiatric diagnosis that may affect subject safety or confound results (e.g., psychosis, bipolar disorder)
* Known history of severe asthma (in the opinion of the investigator) unless deemed currently controlled
* Known history of severe allergic reaction to MPH
* Known history of seizures (except febrile seizures prior to age 5), anorexia nervosa, bulimia or current diagnosis or family history of Tourette's disorder
* Subject who are severely underweight or overweight (in the opinion of the Investigator)
* Any clinical laboratory value outside of the acceptable ranges, unless deemed NCS significant per the Investigator
* Positive history for hepatitis B, hepatitis C or Human Immunodeficiency Virus (HIV)
* Positive screening for illicit drug use, and/or current health conditions or use of medications that might confound the results of the study or increase risk to the subject
* Use of prescription medications (except ADHD medications) within 7 days and over-the-counter medications (except birth control) within the 3 days preceding study enrollment, unless deemed acceptable by the Investigator and Clinical or Medical Monitor
* Participation in clinical trial with an investigational drug within the 30 days preceding study enrollment
* Current suicidal ideation or history of suicidality determined as a significant finding on the C-SSRS by the investigator (Baseline C-SSRS for adolescents; Pediatric Baseline C-SSRS for children).

Primary outcomes:
measure: SKAMP
timeFrame: 8-hours from 8:00 am to 4:00 pm
Secondary outcomes:
Other outcomes:
Locations:
city: Newport Beach
country: United States
facility: AVIDA, Inc.
state: California
city: Marshfield
country: United States
facility: South Shore Psychiatric Services, PC
state: Massachusetts
city: Las Vegas
country: United States
facility: Center for Psychiatry and Behavioral Medicine, Inc.
state: Nevada
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
Study officials:
affiliation: Center for Psychiatry And Behavioral Medicine Inc.
name: Dr. Ann Childress, M.D.
role: PRINCIPAL_INVESTIGATOR
References: